Managing Director Of Bionest Partners

Shows

$Géni\'EAU$

Géni'EAU Épisode 12 - Mise à niveau des StaRREs avec BionestPassionnés de l’eau, plongez au cœur de la modernisation des Stations de Récupération des Ressources de l’Eau (StaRREs). Nous explorons ce sujet en compagnie de deux ingénieurs de chez Bionest, experts du domaine. Ensemble, nous brossons un portrait des infrastructures de traitement des eaux usées au Québec, plongeons dans les défis spécifiques des petites municipalités et découvrons des solutions innovantes disponibles sur le marché. Bonne écoute! N'oubliez pas de vous abonner au balado et de nous suivre sur nos réseaux sociaux pour ne rien manquer! ⁠⁠https://w...

2025-01-1754 min $Géni\'EAU$

Géni'EAU Épisode 11 - Entretien avec BionestPassionnés de l’eau, plongez avec nous dans l’univers de Bionest, une entreprise de Shawinigan à la pointe du traitement autonome des eaux usées. Dans cet épisode, nous avons échangé avec deux de leurs ingénieurs directement depuis leur bureau. Ensemble, nous explorons l’histoire de l’entreprise, découvrons leurs produits et services innovants, discutons de l’importance de la recherche et développement chez eux et jetons un coup d’œil sur leurs projets d’avenir. Bonne écoute ! N'oubliez pas de vous abonner au balado et de nous suivre sur nos réseaux sociaux pour ne rien manquer! ⁠...

2025-01-1729 min

Nosara Podcasts with Rich Burnam Dr. Vanessa introduces BIONEST partnership & DISCOUNT for Nosara residentshttps://richburnam.com/2022/11/23/dr-vanessa-covers-new-wca-and-bionest-partnership-for-affordable-wastewater-solutions-in-nosara/ Dr. Vanessa returns to NP introducing a partnership with Eduardo from Bionest as septic solutions for our rapidly growing community. Dr. Vanessa is a frequent guest who brings high-level people such as Dr. Robert Edgeworth and Nick McCalpin, plus several community info events to NP on a regular basis. In this episode, Vanessa announces a new partnership with BIONEST to promote the installment of conscious and alternative septic solutions. Together with Mr. Eduardo Berrocal from BIONEST they explain the different implementations options, costs associated with installing and maintaining these typ...

2022-11-2421 min

Jon Eakes on CJAD 800AM in Montreal December 18, 2021Topics: Using a snake to unblock a toilet; Battery back-up for a sump pump is not taking a charge – quality back-up systems; Should I drain the plumbing before leaving for Florida; What precautions to take against house plumbing freezing; Have an oil smell on the oil furnace start-up – have furnace inspected for dangerous cracks – you may need a combustion air duct; BIONEST super biologic septic system being used in Renovco’s lakeside mansion renovation; The kitchen drain is slow, will vent valves help?; Loud noise in the wall when the shower runs.

2021-12-1800 min

The Bio Report Extending Precision Medicine Beyond CancerWhile the potential for precision medicine has excited drug developers and clinicians with the promise of delivering more meaningful therapies to patients, the advent of these medicines has largely come in the area of cancer. As the understanding of the biology of other diseases is better understood, efforts to develop precision medicines are advancing into new areas. We spoke to Rachel Laing, managing director of the life sciences consulting firm Bionest, about the state of precision medicine, what can be learned from the experience in cancer, and what it will take to make precision medicine approaches the way we treat...

2020-10-1533 min

The Bio Report Why Diagnostics May Be Critical to Reshaping Alzheimer's Drug DevelopmentAlzheimer’s disease has been a costly and elusive area for drug developers. Despite many promising results in early-stage trials, drug companies have seen millions of dollars of R&D investment end in spectacular late-stage failures. While treatments for the disease are desperately needed, one of the barriers to success has been the availability of diagnostics that can detect the disease at early stages when therapeutic interventions may have their best chance for success. We spoke to Rachel Laing, managing partner of Bionest Partners about the problem, whether there are fundamental misunderstandings about the disease that have sent drug companies in...

2018-05-2417 min

The Bio Report Why Diagnostics May Be Critical to Reshaping Alzheimer’s Drug DevelopmentAlzheimer’s disease has been a costly and elusive area for drug developers. Despite many promising results in early-stage trials, drug companies have seen millions of dollars of R&D investment end in spectacular late-stage failures. While treatments for the disease are desperately needed, one of the barriers to success has been the availability of diagnostics that can detect the disease at early stages when therapeutic interventions may have their best chance for success. We spoke to Rachel Laing, managing partner of Bionest Partners about the problem, whether there are fundamental misunderstandings about the disease that have sent drug companies in...

2018-05-2417 min

The Bio Report Why Biomarkers May Be the Key to Immuno-Oncology SuccessDevelopers of cancer immunotherapies are in a race to find combinations that can distinguish their products for specific indications. Biomarkers, which have played an essential role in the development of targeted therapies, have proven a much more complex challenge in the realm of immuno-oncology. Nevertheless, biomarkers may be the key to winning the competitive battles in immuno-oncology. We spoke to Rachel Laing, managing partner of Bionest Partners, about the role for biomarkers in immuno-oncology, why immuno-oncology companies have much at stake in the hunt for biomarkers that can better select patients for their therapies, and the role biomarkers will play...

2018-05-1026 min

Neurology® Podcast March 13 2018 Issue1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence2. What’s Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnosesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the “What’s Trending” segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelo...

2018-03-1229 min

Neurology® Podcast April 18 2017 IssueShow description/summary:1) Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study2) What's Trending: Alemtuzumab treatment and multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 18, 2017 issue of Neurology. In the first segment, Dr. Michael Jaffee talks with Dr. Karen Schwab about her paper on mild traumatic brain injury in returning soldiers. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Gavin Giovannoni about his paper on alemtuzumab treatment and multiple sclerosis. For more information on traumatic brain injury services for acti...

2017-04-2522 min

Neurology® Podcast March 21 2017 Issue1) Pure autonomic failure: Predictors of conversion to clinical CNS involvement2) What's Trending: ocrelizumab in multiple sclerosis 3) Topic of the Month: neuro-oncologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the March 21, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff interviews Dr. Wolfgang Singer about his paper on pure autonomic failure. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Stephen Hauser about his paper on ocrelizumab in multiple sclerosis. In the next part of the podcast Dr. Kait Nevel focuses her interview with Dr. Lisa DeAngelis on meta...

2017-03-2028 min

Neurology® Podcast October 11 2016 Issue1) Reducing costs while enhancing quality of care in MS2) What's Trending: Interview with Lyell Jones about the topic of the Axon Registry and how it interfaces with practice and reimbursement this is part 2 with part 1 appearing last month 3) Topic of the month: Neurology Today story on the AAN Guideline published in Neurology on the topic of recurrent stroke with patent foramen ovaleThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ilya Kister about his paper on...

2016-10-1128 min

RARECast The Case for Keeping Orphans Where They Can ThriveLarge pharmaceutical companies have grown increasingly interested in rare diseases, but acquisitions of rare disease companies by large biopharmaceutical companies may lead to a cultural mismatch that hinders the development and performance of their products. We spoke to Alain Gilbert, co-chairman of the global strategic consulting firm Bionest Parnters and co-author of a February 2016 analysis in In Vivo “Orphans Should Live Alone.” Gilbert discussed how small, rare disease-focused companies operate differently than large pharmaceutical companies, the essential role their relationship with patients play, and why big companies that acquire rare disease drug developers would be best to leave them alone.

2016-03-2315 min

Neurology® Podcast July 7 2015 Issue1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his...

2015-07-0736 min

Neurology® Podcast April 2 2013 Issue1) NMO spectrum and MS brain lesion and 2) Topic of the month: Stroke trials. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Lucy Matthews about her paper on seropositive NMO spectrum disorder and MS brain lesion distribution. Dr. Adam Numis is reading our e-Pearl of the week about intravascular B-cell lymphoma. In the next part of the podcast Dr. Brett Kissela interviews Dr. Joseph Broderick about IMS III trial. All the participants have disclosures.Dr. Keegan...

2013-04-0222 min

BioBusiness.TV, the podcast! ver2 IMCL + BMS Deal Review with Katherine KimYou are Watching: ImClone likely to be Acquired by BMS in the $65-70 range, says Katherine Kim [BoA] Was BMS’ offer to ImClone shareholders to be expected? What was Carl Icahn’s role? How is ImClone’s stock to be valued by BMS and other shareholders? Katherine Kim takes an in-depth look at the drugs, the pipeline, the markets and indications, and benchmark premiums. She believes this deal is very likely to close, and when it does, it will be in the $65-70 range. This interview was conducted at the NASDAQ Marketsite, on August 25th, 2008, in New York City. Featuring: * Kather...

2008-08-2501 min

BioBusiness.TV, the podcast! ver2 DNA + ROCHE Deal Review with Katherine KimYou are Watching: Genentech / Roche, Good Time for a Deal; Talent Unlikely to be Retained, says Katherine Kim [BoA] Genentech is at a turning point, and the time would be right for an acquisition by Roche (if there were any). Her price target is $110 per share. Katherine and Daniel review the value drivers in Genentech, and the willingness of both Roche and Genentech CEOs to make this deal happen. This interview was conducted at the NASDAQ Marketsite, on August 25th, 2008, in New York City. Featuring: * Katherine S. Kim, Principal and Senior Biotech Analyst, Banc of America Securities * Daniel Teper, Managing...

2008-08-2501 min

BioBusiness.TV, the podcast! ver2 Katherine Kim on Sector Cash InflowYou are Watching: Maturing Biotech Sector Likely to see Large Cash Inflow after Genentech & ImClone Deals, says Katherine Kim [BoA] The $60+Bn generated from large cap acquisitions are likely to be reinvested in biotech, specifically in 4 tranches of the sector. Katherine Kim reviews gives us the rationales behind this thinking. She also expects increased M&A activity in the years to come. This interview was conducted at the NASDAQ Marketsite, on August 25th, 2008, in New York City. Featuring: * Katherine S. Kim, Principal and Senior Biotech Analyst, Banc of America Securities * Daniel Teper, Managing Director at Bionest Partners, and Founder & Chairman...

2008-08-2504 min

BioBusiness.TV, the podcast! ver2 MYGN Stock Analysis with Charles DuncanYou are Watching: Myriad Genetics, Unique Hybrid Business Model, $48 to $87 Share Price? The story of Myriad Genetics (MYGN) resonated in the investor community as disappointing Phase 3 data was followed by a 40% stock price increase (from $48 on June 27 to $66 on August 20th, day of this interview). Charles Duncan has the longest formal coverage on Myriad. He explains the rationale behind this development, and the $87 price target he has set for the company shares. Charles and Daniel review Myriad’s personalized medicine and drug development hybrid business model, and their prospects for growth as standalone companies. Would spinning of the drug development bu...

2008-08-2011 min

BioBusiness.TV, the podcast! ver2 DNA + Roche Deal Review with Mike KingYou are Watching: Roche and Genentech, Deal Review, with Mike King. Mike King and Daniel Teper discuss the Genentech / Roche deal. Genentech’s Board of Directors say $89 per share is inadequate, Roche’s management feels it is more than generous. Genentech shareholders like this stock, and are reluctant to sell for less than $120-135. Why does Roche want the remaining 56% of Genentech? Will Roche be able to retain the innovation that made Genentech so successful? What are the odds of this deal closing? This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City. Featuring: * Michael King...

2008-08-1301 min

BioBusiness.TV, the podcast! ver2 IMCL + BMS Deal Review with Mike KingYou are Watching: BMS and ImClone Deal Review, with Mike King. Why is BMS after ImClone, and what will happen next? Carl Icahn’s says the $60 bid is too low. Mike King believes Icahn is waiting for the Genentech Roche transaction to play out, in order to see the valuation metrics that will be used in that transaction. Mike and Daniel continue to discuss the integration of ImClone within BMS, the international rights to Erbitux, and the odds of this transaction closing. This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City. Featuring: * Michael King, Di...

2008-08-1301 min

BioBusiness.TV, the podcast! ver2 Mike King on Summer AcquisitionsYou are Watching: Impact of Summer Acquisitions on the Biotech Industry, with Mike King. With close to $60Bn worth of biotech stock that could be removed from the market, where will this money go? Where will investors be putting their money? Mike thinks it will flow back into the group as there are still some attractive investment opportunities. Mike and Daniel further discuss the disappearance of the large cap leaders, who would take over the leadership position, and the potential for future acquisitions. This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City. Featuring: * Michael...

2008-08-1304 min

BioBusiness.TV, the podcast! ver2 CELG Stock Analysis with Charles DuncanYou are Watching: Celgene's Revlimid, Markets and Revenues, with Charles Duncan. What are the next areas of growth for Revlimid? Asides from the growth in frontline use for Multiple Myeloma, Charles Duncan tells us about its use in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Revlimid is also bound to expand its geographical reach with Europe and Japan. Charles' expectation is that Revlimid will be a $2.8+ billion opportunity drug. Finally, he explains Revlimid's contribution to Celgene's bottom line and stock price. Charles' price target for CELG is $85. This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in...

2008-06-2601 min

BioBusiness.TV, the podcast! ver2 CELG vs. MLNM with Charles DuncanYou are Watching: Oncology Battlegrounds: Celgene vs. Millenium, with Charles Duncan. The long running face off between Celgene's Revilimid and Millenium's Velcade intensifies with the latest clinical data releases. Charles Duncan, is bullish on Revlimid, he tells us why. Charles looks at the impact of Takeda's new ownership of Millenium on its management and competitivity vs. Celgene. Charles also comments on the JNJ / Takeda relationship. This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in New York City. Featuring: * Charles Duncan, Managing Director and Senior Biotechnology Analyst, JMP Securities * Daniel Teper, Managing Director at Bionest Partners, and Founder...

2008-06-2601 min

BioBusiness.TV, the podcast! ver2 DNA vs. IMCL with Charles DuncanYou are Watching: Oncology Battlegrounds: Genentech vs. ImClone, with Charles Duncan. The data released on Eribitux at the latest ASCO meeting is an indicator of the emergence of personalized medicine. The data itself was not that great of news for ImClone. Nonetheless, it will lift some of the pressure from reimbursement authorities. Charles believes the KRAS mutational status will be on the labels. Genentech remains strong in its growth and earnings. ImClone's new data also affects Genentech indirectly, and in a positive way. This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in New York City. Featuring: * Charles...

2008-06-2601 min

BioBusiness.TV, the podcast! ver2 Small Cap Focus with Charles DuncanYou are Watching: Small Cap Focus, Full Integration, Personalized Medicine, with Charles Duncan. In today's market, where good clinical data and milestones are shadowed by financing prospects, Charles Duncan recommends having at least 2 years cash. Charles also presents a few of the most promising small and mid caps he's been keeping his eyes on - including Myriad Genetics (MYGN), Sequanom (SQNM), Illumina (ILMN), Invitrogen (IVGN), Genomic Health (GHDX). Charles and Daniel discuss the opportunity for small and mid caps to become fully integrated specialty pharmaceuticals. This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in New York City. ...

2008-06-2601 min

BioBusiness.TV, the podcast! ver2 ASCO 2008 Review - Part 1: The Take HomeYou are Watching: ASCO 2008, the take home message with Mike King. What should all investors know about this year’s ASCO? What is the take home message? Mike King tells us it hasn't been a momentous ASCO. ImClone was most affected. Mike and Daniel look at the behavior of stocks before and after the meeting, and reflect on the impact of abstract releases, preceding this year's ASCO. This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in New York City, on the occasion of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Featuring: * Michael Ki...

2008-06-0502 min

BioBusiness.TV, the podcast! ver2 ASCO 2008 Review - Part 2: IMCLYou are Watching: ASCO 2008, Focus on Imclone with Mike King. What happened to ImClone's stock after ASCO this year? Mike King tells us about the expectations, the fluctuations, and what he believes was a misinterpretation of the FLEX trial results. Mike foresees a strong market for Erbitux, in the years to come, with positive impact on ImClone's earnings. Also discussed in this interview is the KRAS mutation, its impact on Erbitux's market penetration and on Imclone's earning, as well as the interest doctors and payers have in it. This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in...

2008-06-0501 min

BioBusiness.TV, the podcast! ver2 ASCO 2008 Review - Part 3: DNAYou are Watching: ASCO 2008, Focus on Genentech with Mike King. In a Post-ASCO review Mike King reviews Genentech. Can the 2 months Avastin and 5 weeks Erbitux data be compared? Apples and oranges, according to Mike! The subgroups tell a completely different story. Mike is optimistic with regard to Genentech's performance. It has seen a strong growth in Non Small Cell Lung Cancer (NSCLC), and should see growth in Metastatic Breast Cancer too. Mike sets a $92 price target on Genentech's stock; outperform. Update: Genentech’s stock (DNA) reached $93.88 on July 21st, from $73 on the day of this interview. Hats off! This interview wa...

2008-06-0501 min

BioBusiness.TV, the podcast! ver2 ASCO 2008 Review - Part 4: CELGYou are Watching: ASCO 2008, Focus on Celgene with Mike King. Celgene in a Post-ASCO review, reveals positive data. Mike King discusses the multiple myeloma survival data and its impact on Revlimid. Mike compares Celgene's Revlimid and (Takeda's) Millenium's Velcade. Is complete response the best predictor of outcome? How do the other parameters of the studies come into play? Mike gives us a projection for the sales of Revlimid and a price target for Celgene at $72. Last he touches upon the question of Celgene's acquisition. Would it make any sense? Update: Celgene’s stock (CELG) reached $72.63 on July 21st, from $63.35 on th...

2008-06-0501 min

BioBusiness.TV, the podcast! ver2 ASCO 2008 Review - Part 5: Small CapsYou are Watching: ASCO 2008, Small Cap Focus with Mike King. ASCO can be full of surprises for some of the smaller caps. Mike King from Rodman & Renshaw reviews a few names that include Poiniard, MedRx, and Celldex/Avant. This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in New York City, on the occasion of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Featuring: * Michael King, Director of Research, Rodman & Renshaw * Daniel Teper, Managing Director of Bionest Partners, and Founder & Chairman of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM...

2008-06-0501 min